Gyre Therapeutics, Inc. Revenue from Grants (Deprecated 2018-01-31)
Gyre Therapeutics, Inc. (GYRE) reported Revenue from Grants (Deprecated 2018-01-31) of $275.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromGrants · last filed 2015-03-16
- Gyre Therapeutics, Inc. revenue from grants (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $127.00K.
- Gyre Therapeutics, Inc. revenue from grants (deprecated 2018-01-31) for the quarter ending 2014-09-30 was $25.00K.
- Gyre Therapeutics, Inc. revenue from grants (deprecated 2018-01-31) for the quarter ending 2014-06-30 was $36.00K.
- Gyre Therapeutics, Inc. revenue from grants (deprecated 2018-01-31) for the quarter ending 2014-03-31 was $87.00K.
- Gyre Therapeutics, Inc. revenue from grants (deprecated 2018-01-31) for fiscal 2014 was $275.00K, a 195.70% increase from fiscal 2013.
- Gyre Therapeutics, Inc. revenue from grants (deprecated 2018-01-31) for fiscal 2013 was $93.00K, a 78.86% decline from fiscal 2012.
- Gyre Therapeutics, Inc. revenue from grants (deprecated 2018-01-31) for fiscal 2012 was $440.00K, a 33.13% decline from fiscal 2011.
- Gyre Therapeutics, Inc. revenue from grants (deprecated 2018-01-31) for fiscal 2011 was $658.00K, a 71.80% decline from fiscal 2010.
| Period end | Revenue from Grants (Deprecated 2018-01-31) 3 month | Revenue from Grants (Deprecated 2018-01-31) 6 month | Revenue from Grants (Deprecated 2018-01-31) 9 month | Revenue from Grants (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2014-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $152.00K derived: sum of 2 quarters · filed 2015-03-16 | $188.00K derived: sum of 3 quarters · filed 2015-03-16 | $275.00K 10-K · filed 2015-03-16 |
| 2014-09-30 | $25.00K 10-Q · filed 2014-11-06 | $61.00K derived: sum of 2 quarters · filed 2014-11-06 | $148.00K 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $36.00K 10-Q · filed 2014-08-07 | $123.00K 10-Q · filed 2014-08-07 | ||
| 2014-03-31 | $87.00K 10-Q · filed 2014-05-08 | |||
| 2013-12-31 | $93.00K 10-K · filed 2015-03-16 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $32.00K derived: sum of 2 quarters · filed 2015-03-16 | $190.00K derived: sum of 3 quarters · filed 2015-03-16 | $440.00K 10-K · filed 2015-03-16 |
| 2012-09-30 | $32.00K 10-Q · filed 2013-11-06 | $190.00K derived: sum of 2 quarters · filed 2013-11-06 | $440.00K 10-Q · filed 2013-11-06 | $565.00K derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-06-30 | $158.00K 10-Q · filed 2013-08-07 | $408.00K 10-Q · filed 2013-08-07 | $533.00K derived: sum of 3 quarters · filed 2014-03-14 | $950.00K derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-03-31 | $250.00K 10-Q · filed 2013-05-08 | $375.00K derived: sum of 2 quarters · filed 2014-03-14 | $792.00K derived: sum of 3 quarters · filed 2014-03-14 | $836.00K derived: sum of 4 quarters · filed 2014-03-14 |
| 2011-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $542.00K derived: sum of 2 quarters · filed 2014-03-14 | $586.00K derived: sum of 3 quarters · filed 2014-03-14 | $658.00K 10-K · filed 2014-03-14 |
| 2011-09-30 | $417.00K 10-Q · filed 2012-11-08 | $461.00K derived: sum of 2 quarters · filed 2012-11-08 | $533.00K 10-Q · filed 2012-11-08 | $2.10M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-06-30 | $44.00K 10-Q · filed 2012-08-09 | $116.00K 10-Q · filed 2012-08-09 | $1.69M derived: sum of 3 quarters · filed 2013-03-15 | $1.82M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-03-31 | $72.00K 10-Q · filed 2012-05-09 | $1.64M derived: sum of 2 quarters · filed 2013-03-15 | $1.78M derived: sum of 3 quarters · filed 2013-03-15 | $1.98M derived: sum of 4 quarters · filed 2013-03-15 |
| 2010-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $1.71M derived: sum of 2 quarters · filed 2013-03-15 | $1.90M derived: sum of 3 quarters · filed 2013-03-15 | $2.33M 10-K · filed 2013-03-15 |
| 2010-09-30 | $136.00K 10-Q · filed 2011-11-03 | $334.00K derived: sum of 2 quarters · filed 2011-11-03 | $763.00K 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $198.00K 10-Q · filed 2011-08-09 | $627.00K 10-Q · filed 2011-08-09 | ||
| 2009-12-31 | $409.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |